2022
DOI: 10.1111/1756-185x.14491
|View full text |Cite
|
Sign up to set email alerts
|

Leflunomide: Traditional immunosuppressant with concurrent antiviral effects

Abstract: Leflunomide is a classic disease‐modifying anti‐rheumatic drug that is widely used to treat autoimmune diseases. Studies also show its antiviral effects in in vitro and/or in vivo experiments. Considering glucocorticoids, immunosuppressants and newly emerged antibodies commonly used in autoimmune diseases and autoinflammatory disorders bring risk of infection such as viral infection, leflunomide with combination of anti‐viral and immunosuppressive features to maintain the balance between infection and anti‐inf… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 75 publications
0
0
0
Order By: Relevance
“…Leflunomide and fluoroquinolones are readily available and relatively well-tolerated. However, leflunomide has a potential risk of leukopenia, peripheral neuropathy, gastrointestinal effects, and liver dysfunction or damage[ 57 ]. Fluoroquinolones pose a risk of gastrointestinal effects, tendinitis, tendinopathy, tendon rupture, aortic aneurysm and dissection, neuropathy, arrhythmia, and labile blood sugars[ 58 ] and potentially higher rates of fluoroquinolone-resistant infections.…”
Section: Discussionmentioning
confidence: 99%
“…Leflunomide and fluoroquinolones are readily available and relatively well-tolerated. However, leflunomide has a potential risk of leukopenia, peripheral neuropathy, gastrointestinal effects, and liver dysfunction or damage[ 57 ]. Fluoroquinolones pose a risk of gastrointestinal effects, tendinitis, tendinopathy, tendon rupture, aortic aneurysm and dissection, neuropathy, arrhythmia, and labile blood sugars[ 58 ] and potentially higher rates of fluoroquinolone-resistant infections.…”
Section: Discussionmentioning
confidence: 99%